Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV
Author:
Affiliation:
1. Gilead Sciences, Inc, Foster City
2. Quest Clinical Research, San Francisco, California
3. DP Clinical, Rockville, Maryland
4. Merck & Co, Inc, Kenilworth, New Jersey
5. KCAS Bioanalytical & Biomarker Services, Shawnee, Kansas, USA.
Abstract
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference30 articles.
1. Long-term HIV/AIDS survivors: patients living with HIV infection retained in care for over 20 years. What have we learned?;Krentz;Int J STD AIDS,2018
2. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice;Imaz;AIDS Rev,2011
3. Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomes;Jones;Arch Intern Med,2008
4. The pharmacology of HIV drug resistance;Zdanowicz;Am J Pharm Educ,2006
5. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel;Saag;JAMA,2020
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?;HIV/AIDS - Research and Palliative Care;2023-11
2. Alternative options for treatment-experienced people with HIV;AIDS;2023-06-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3